These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38012890)

  • 1. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
    Wajja A; Nassanga B; Natukunda A; Serubanja J; Tumusiime J; Akurut H; Oduru G; Nassuuna J; Kabagenyi J; Morrison H; Scott H; Doherty RP; Marshall JL; Puig IC; Cose S; Kaleebu P; Webb EL; Satti I; McShane H; Elliott AM;
    Lancet Infect Dis; 2024 Mar; 24(3):285-296. PubMed ID: 38012890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
    Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
    Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
    Audran R; Karoui O; Donnet L; Soumas V; Fares F; Lovis A; Noirez L; Cavassini M; Fayet-Mello A; Satti I; McShane H; Spertini F
    J Infect; 2024 Aug; 89(2):106205. PubMed ID: 38897242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
    Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
    Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
    Whelan KT; Pathan AA; Sander CR; Fletcher HA; Poulton I; Alder NC; Hill AV; McShane H
    PLoS One; 2009 Jun; 4(6):e5934. PubMed ID: 19529780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
    Wajja A; Kizito D; Nassanga B; Nalwoga A; Kabagenyi J; Kimuda S; Galiwango R; Mutonyi G; Vermaak S; Satti I; Verweij J; Tukahebwa E; Cose S; Levin J; Kaleebu P; Elliott AM; McShane H
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005440. PubMed ID: 28472067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
    Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
    Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
    Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
    Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
    Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
    Pathan AA; Minassian AM; Sander CR; Rowland R; Porter DW; Poulton ID; Hill AV; Fletcher HA; McShane H
    Vaccine; 2012 Aug; 30(38):5616-24. PubMed ID: 22789508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
    Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
    PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
    Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
    Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
    Minhinnick A; Satti I; Harris S; Wilkie M; Sheehan S; Stockdale L; Manjaly Thomas ZR; Lopez-Ramon R; Poulton I; Lawrie A; Vermaak S; Le Vert A; Del Campo J; Hill F; Moss P; McShane H
    Vaccine; 2016 Mar; 34(11):1412-21. PubMed ID: 26854906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MVA85A vaccine to enhance BCG for preventing tuberculosis.
    Kashangura R; Jullien S; Garner P; Johnson S
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012915. PubMed ID: 31038197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
    Folegatti PM; Bittaye M; Flaxman A; Lopez FR; Bellamy D; Kupke A; Mair C; Makinson R; Sheridan J; Rohde C; Halwe S; Jeong Y; Park YS; Kim JO; Song M; Boyd A; Tran N; Silman D; Poulton I; Datoo M; Marshall J; Themistocleous Y; Lawrie A; Roberts R; Berrie E; Becker S; Lambe T; Hill A; Ewer K; Gilbert S
    Lancet Infect Dis; 2020 Jul; 20(7):816-826. PubMed ID: 32325038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
    Prentice S; Nassanga B; Webb EL; Akello F; Kiwudhu F; Akurut H; Elliott AM; Arts RJW; Netea MG; Dockrell HM; Cose S;
    Lancet Infect Dis; 2021 Jul; 21(7):993-1003. PubMed ID: 33609457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
    Rowland R; Pathan AA; Satti I; Poulton ID; Matsumiya MM; Whittaker M; Minassian AM; O'Hara GA; Hamill M; Scott JT; Harris SA; Poyntz HC; Bateman C; Meyer J; Williams N; Gilbert SC; Lawrie AM; Hill AV; McShane H
    Hum Vaccin Immunother; 2013 Jan; 9(1):50-62. PubMed ID: 23143773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.